Soriot Stands By His Post-Pfizer Sales Pledge For AstraZeneca

 
• By Eleanor Malone

Pascal Soriot stands by the ambitious growth target he set for AstraZeneca in his defense against Pfizer's 2014 bid for the company. Any shortfall in the target of $45bn by 2023 will reflect the weakening of the dollar rather than product challenges for the UK company, the bullish CEO told Scrip one day after the company delivered disappointing Phase III data that slashed around 15% from its share price.

Arrow flying to target with radial motion blur
AstraZeneca's Soriot still confident of hitting long-range target

More from Leadership

More from Scrip